Agenus - Stock Price History | AGEN

Historical daily share price chart and data for Agenus since 2023 adjusted for splits. The latest closing stock price for Agenus as of January 27, 2023 is 2.63.
  • The all-time high Agenus stock closing price was 315.78 on March 09, 2000.
  • The Agenus 52-week high stock price is 3.37, which is 28.1% above the current share price.
  • The Agenus 52-week low stock price is 1.25, which is 52.5% below the current share price.
  • The average Agenus stock price for the last 52 weeks is 2.43.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Agenus Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2022 2.4495 3.4700 3.4700 1.3000 2.4000 -25.47%
2021 4.3285 3.2300 6.6300 2.5600 3.2200 1.26%
2020 3.5027 4.0400 5.2000 1.9200 3.1800 -21.87%
2019 3.0215 2.5100 4.4000 2.1700 4.0700 71.01%
2018 3.0122 3.5400 6.0400 1.5900 2.3800 -26.99%
2017 3.9090 4.1600 5.3700 3.2400 3.2600 -20.87%
2016 4.5745 4.4600 7.3600 2.7200 4.1200 -9.25%
2015 6.1392 3.9800 9.7800 3.8800 4.5400 14.36%
2014 3.2013 2.7800 5.1000 2.4100 3.9700 50.38%
2013 3.6174 4.2400 4.9300 2.4000 2.6400 -35.61%
2012 4.6131 2.1700 7.0400 2.1000 4.1000 105.00%
2011 4.3574 6.3600 6.6600 2.0000 2.0000 -67.00%
2010 5.3960 3.8556 8.2800 3.6006 6.0600 57.81%
2009 7.1504 2.8800 17.9400 1.8000 3.8400 33.33%
2008 10.4911 12.4800 18.1800 2.4600 2.8800 -76.47%
2007 14.9767 11.5200 26.5800 9.4200 12.2400 11.48%
2006 16.6496 28.7400 41.4600 9.2400 10.9800 -61.55%
2005 37.7911 60.0000 60.0000 28.5600 28.5600 -52.96%
2004 51.7704 68.7600 73.0800 28.3200 60.7200 -10.76%
2003 66.5551 64.2000 94.8000 42.7800 68.0400 10.74%
2002 65.3534 92.9400 100.9800 41.1660 61.4400 -37.56%
2001 95.8940 66.3600 120.6000 64.5000 98.4000 48.28%
2000 117.9851 277.5000 315.7800 63.7800 66.3600 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.744B $0.296B
Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.188B 9.47
GSK (GSK) United Kingdom $72.345B 9.01
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.333B 19.34
Ginkgo Bioworks Holdings (DNA) United States $3.395B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.672B 25.10
Biohaven (BHVN) United States $1.264B 0.00
Emergent Biosolutions (EBS) United States $0.655B 5.15
ADC Therapeutics SA (ADCT) Switzerland $0.363B 0.00
Ambrx Biopharma (AMAM) United States $0.073B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
SQZ Biotechnologies (SQZ) United States $0.025B 0.00